SI
IMNM icon

Sofinnova Investments’s Immunome IMNM Stock Holding History

Sofinnova Investments’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.5M Buy
1,720,316
+18,412
+1% +$394K 1.88% 19
2026
Q1 		$37.2M Buy
1,701,904
+83,427
+5% +$1.86M 1.41% 25
2025
Q4 		$34.8M Buy
1,618,477
+1,182,426
+271% +$20.8M 1.5% 22
2025
Q3 		$5.11M Sell
436,051
-342,425
-44% -$3.41M 0.28% 53
2025
Q2 		$7.24M Sell
778,476
-10,190
-1% -$83.5K 0.44% 47
2025
Q1 		$5.31M Buy
788,666
+41,842
+6% +$401K 0.35% 51
2024
Q4 		$7.93M Buy
746,824
+70,058
+10% +$847K 0.58% 38
2024
Q3 		$9.89M Buy
676,766
+21,086
+3% +$300K 0.79% 29
2024
Q2 		$7.93M Buy
655,680
+61,284
+10% +$959K 0.41% 47
2024
Q1 		$14.7M Buy
+594,396
New +$12.1M 0.82% 32

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Sofinnova Investments's IMNM Position: Q2 2026 in Review

Sofinnova Investments increased its Immunome (IMNM) stake by 1.1% in Q2 2026, buying an estimated $394K and bringing the position to 1,720,316 shares worth $36.5M. The position accounts for 1.88% of the portfolio, ranked #19.

Sofinnova Investments first reported a position in IMNM in Q1 2024 and has held it in 10 quarters since. The position peaked at $37.2M in Q1 2026. 202 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Sofinnova Investments held 1,720,316 shares of Immunome worth $36.5M as of Q2 2026.
  • Sofinnova Investments bought 18,412 Immunome shares in Q2 2026, an estimated $394K.
  • Immunome made up 1.88% of Sofinnova Investments's portfolio in Q2 2026, its #19 holding.
  • Sofinnova Investments first reported a position in Immunome in Q1 2024 and has held it in 10 quarters since.
  • Sofinnova Investments's Immunome position peaked at $37.2M in Q1 2026.
  • 202 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Sofinnova Investments's 13F filing for Q2 2026, filed 14 Aug 2026.